Analyst is bullish on Vertex Pharmaceuticals, citing FDA approval for JOURNAVX and strong earnings growth potential in 2025.
The U.S. Food and Drug Administration (FDA) approved Journavx (suzetrigine) oral tablets on Thursday as a first-in-class ...
Dr. Sanjay Gupta said Tuesday that the approval of a new non-opioid pain medication is “a pretty big deal.” “This is a pretty ...
The U.S. Food and Drug Administration (FDA) approved Thursday a new type of prescription pain medication for moderate to ...
The FDA’s nod for suzetrigine bolsters confidence in the pharmaceutical industry’s strategy to target sodium channels.
It was given to people who had acute surgical pain from either abdominoplasty, also known as a tummy tuck, or bunion surgery.
( The Hill) – The U.S. Food and Drug Administration (FDA) approved Journavx (suzetrigine) oral tablets on Thursday as a first ...
People of color now have less access to prescription opioid painkillers than white patients, an unintended consequence of ...
If the attention generated by BioSpace’s coverage of this landmark approval is any indication, Americans are hungry for ...
"A new non-opioid analgesic therapeutic class for acute pain ... patients with another treatment option," FDA Center for Drug Evaluation and Research Acting Director Dr. Jacqueline Corrigan ...
Today, the U.S. Food and Drug Administration (FDA) gave its approval to Vertex Pharmaceuticals' (NASDAQ: NASDAQ:VRTX) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results